의약품 정밀화학 시장 보고서 : 유형, 제품, 사이즈, 용도, 지역별(2025-2033년)

The global pharmaceutical fine chemicals market size reached USD 149.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 244.7 Billion by 2033, exhibiting a growth rate (CAGR) of 5.38% during 2025-2033.

Fine chemicals refer to a set of pure and complex chemicals that are manufactured in limited quantities at higher prices. They are produced in multipurpose plants with the support of a multistep batch biotechnological method. Unlike specialty chemicals, these substances are accumulated precisely based on their distinct functional characteristics and specific molecular properties. After collection, fine chemicals are used as key agents, stabilizers, and solvents for producing several pharmaceutical chemical products, including magnesium stearate and gelatin. At present, they are commercially available in proprietary and non-proprietary variants.

Pharmaceutical Fine Chemicals Market Trends:

The increasing prevalence of various neurological and cardiovascular diseases, including arrhythmias, stroke, cancer, and coronary artery ailments, especially amongst the geriatric population, is one of the prime factors driving the pharmaceutical fine chemical market toward growth. In line with this, favorable initiatives undertaken by the government bodies of several nations for introducing novel vaccines, drugs, and pharmaceutical medications for retaliating against coronavirus diseases (COVID-19) and several other disorders is further facilitating the widespread adoption of these medications in the healthcare sector. This, in turn, is acting as another growth-inducing factor in the market. Additionally, enforcement of different guidelines for utilizing pharmaceutical fine chemicals as raw materials to manufacture medicines, while meeting the quality standards is contributing to the market growth. Other factors, such as significant expansion in the pharmaceutical industry, increasing investments in the research and development (R&D) activities, and the growing consumer awareness regarding numerous disorders and the available medication options, are creating a positive outlook for the market across the globe.

Key Market Segmentation:

Breakup by Type:

• Proprietary
• Non-proprietary

Breakup by Product:

• Active Ingredients
• Basic Building Blocks
• Advanced Intermediates

Breakup by Size:

• Big Molecules
• Small Molecules

Breakup by Application:

• Cardiovascular
• Neurological
• Oncological
• Respiratory
• Gastrointestinal
• Musculoskeletal
• Others

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being BASF SE, Borregaard ASA, CHEMADA Industries Ltd. (Turpaz), Denisco Chemicals Pvt Ltd, Dupont De Nemours Inc., Eastman Chemical Company, Evonik Industries AG, Koninklijke DSM N.V., Lonza Group AG, Solvay S.A., Syntor Fine Chemicals Ltd. (Aceto Corporation) and W. R. Grace and Co. (Standard Industries Inc.).

Key Questions Answered in This Report

• 1.How big is the global pharmaceutical fine chemicals market?
• 2.What is the expected growth rate of the global pharmaceutical fine chemicals market during 2025-2033?
• 3.What are the key factors driving the global pharmaceutical fine chemicals market?
• 4.What has been the impact of COVID-19 on the global pharmaceutical fine chemicals market?
• 5.What is the breakup of the global pharmaceutical fine chemicals market based on the type?
• 6.What is the breakup of the global pharmaceutical fine chemicals market based on the product?
• 7.What is the breakup of the global pharmaceutical fine chemicals market based on the size?
• 8.What are the key regions in the global pharmaceutical fine chemicals market?
• 9.Who are the key players/companies in the global pharmaceutical fine chemicals market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Pharmaceutical Fine Chemicals Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Proprietary
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Non-proprietary
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Product

• 7.1 Active Ingredients
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Basic Building Blocks
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Advanced Intermediates
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Size

• 8.1 Big Molecules
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Small Molecules
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by Application

• 9.1 Cardiovascular
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Neurological
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Oncological
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Respiratory
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast
• 9.5 Gastrointestinal
  • 9.5.1 Market Trends
  • 9.5.2 Market Forecast
• 9.6 Musculoskeletal
  • 9.6.1 Market Trends
  • 9.6.2 Market Forecast
• 9.7 Others
  • 9.7.1 Market Trends
  • 9.7.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 BASF SE
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 Borregaard ASA
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
  • 15.3.3 CHEMADA Industries Ltd. (Turpaz)
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
  • 15.3.4 Denisco Chemicals Pvt Ltd
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
  • 15.3.5 Dupont De Nemours Inc.
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 Financials
    • 15.3.5.4 SWOT Analysis
  • 15.3.6 Eastman Chemical Company
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
    • 15.3.6.3 Financials
    • 15.3.6.4 SWOT Analysis
  • 15.3.7 Evonik Industries AG
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
    • 15.3.7.4 SWOT Analysis
  • 15.3.8 Koninklijke DSM N.V.
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Lonza Group AG
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 Solvay S.A.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis
  • 15.3.11 Syntor Fine Chemicals Ltd. (Aceto Corporation)
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
  • 15.3.12 W. R. Grace and Co. (Standard Industries Inc.)
    • 15.3.12.1 Company Overview
    • 15.3.12.2 Product Portfolio
    • 15.3.12.3 SWOT Analysis